AstraZeneca unit holds 7.8% stake in Monopar

AstraZeneca PLC, through its wholly owned subsidiary Alexion Pharmaceuticals, Inc., has filed Amendment No. 1 to a Schedule 13G reporting its beneficial ownership in Monopar Therapeutics Inc. common stock.

Accepted by SEC EDGAR 02/06/2026 - 09:54 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

AstraZeneca PLC, through its wholly owned subsidiary Alexion Pharmaceuticals, Inc., has filed Amendment No. 1 to a Schedule 13G reporting its beneficial ownership in Monopar Therapeutics Inc. common stock.

The filing states that Alexion directly holds 522,667 shares of Monopar common stock, representing 7.8% of the outstanding shares, based on 6,682,584 shares outstanding as of October 31, 2025, as reported in Monopar’s Form 10-Q. AstraZeneca PLC and Alexion may each be deemed to have sole voting and sole dispositive power over these shares.

The reporting persons certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Monopar, and are not held in connection with any transaction having that purpose or effect.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What ownership stake does AstraZeneca report in Monopar Therapeutics (MNPR)?

AstraZeneca, through Alexion Pharmaceuticals, reports beneficial ownership of 522,667 Monopar shares. This represents 7.8% of Monopar’s common stock, based on 6,682,584 shares outstanding as of October 31, 2025, as disclosed in Monopar’s Form 10-Q.

Who directly holds the Monopar Therapeutics (MNPR) shares reported in this Schedule 13G/A?

The 522,667 Monopar shares are directly held by Alexion Pharmaceuticals, Inc., a wholly owned subsidiary of AstraZeneca PLC. Both AstraZeneca and Alexion may each be deemed to have sole voting and sole dispositive power over these shares under SEC rules.

What percentage of Monopar Therapeutics’ common stock does 522,667 shares represent?

The filing states that 522,667 shares represent 7.8% of Monopar’s outstanding common stock. This percentage is calculated using 6,682,584 shares outstanding as of October 31, 2025, as reported in Monopar’s Quarterly Report on Form 10-Q filed November 13, 2025.

Is AstraZeneca seeking to influence control of Monopar Therapeutics (MNPR) with this stake?

The reporting persons certify the shares were not acquired and are not held to change or influence control of Monopar. They also state the holdings are not in connection with any transaction having that purpose or effect, consistent with a passive Schedule 13G filing.

What type of SEC filing is this for Monopar Therapeutics (MNPR)?

This is Amendment No. 1 to a Schedule 13G, a beneficial ownership report. It updates AstraZeneca PLC and Alexion Pharmaceuticals, Inc.’s disclosed holdings in Monopar common stock, including total shares, percentage of the class, and associated voting and dispositive powers.

What voting and dispositive power do AstraZeneca and Alexion report over Monopar (MNPR) shares?

The filing reports sole voting power over 522,667 shares and sole dispositive power over 522,667 shares for both AstraZeneca PLC and Alexion Pharmaceuticals, Inc. It reports zero shared voting power and zero shared dispositive power for these Monopar common shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Monopar Therapeutics Inc.

(Name of Issuer)

Common Stock, $0.001 par value per share

(Title of Class of Securities)

61023L207

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 61023L207

1

Names of Reporting Persons

AstraZeneca PLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 522,667.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 522,667.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

522,667.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.8 %

12

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person: Note to Rows 5, 7 and 9: Represents shares directly held by Alexion Pharmaceuticals, Inc., a wholly-owned subsidiary of AstraZeneca PLC. AstraZeneca PLC and Alexion Pharmaceuticals, Inc. may each be deemed to have sole voting and dispositive power over the shares. Note to Row 11: Based upon 6,682,584 shares of Common Stock of the Issuer outstanding as of October 31, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q ("Form 10-Q") filed with the Securities and Exchange Commission (the "SEC") on November 13, 2025.

SCHEDULE 13G

CUSIP No. 61023L207

1

Names of Reporting Persons

Alexion Pharmaceuticals, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 522,667.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 522,667.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

522,667.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.8 %

12

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person: Note to Rows 5, 7 and 9: Represents shares directly held by Alexion Pharmaceuticals, Inc., a wholly-owned subsidiary of AstraZeneca PLC. AstraZeneca PLC and Alexion Pharmaceuticals, Inc. may each be deemed to have sole voting and dispositive power over the shares. Note to Row 11: Based upon 6,682,584 shares of Common Stock of the Issuer outstanding as of October 31, 2025, as reported in the Issuer's Form 10-Q filed with the SEC on November 13, 2025.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Monopar Therapeutics Inc.
(b)	Address of issuer's principal executive offices: 1000 Skokie Blvd., Suite 350 Wilmette, IL, 60091
Item 2.
(a)	Name of person filing: See response to Item 2(c).
(b)	Address or principal business office or, if none, residence: See response to Item 2(c).
(c)	Citizenship: This statement is filed on behalf of: AstraZeneca PLC 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA Citizenship: United Kingdom Alexion Pharmaceuticals, Inc. 121 Seaport Boulevard Boston, Massachusetts 02210 Citizenship: United States of America
(d)	Title of class of securities: Common Stock, $0.001 par value per share
(e)	CUSIP No.: 61023L207
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 522,667 shares
(b)	Percent of class: 7.8%. Based upon 6,682,584 shares of Common Stock of the Issuer outstanding as of October 31, 2025, as reported in the Issuer's Form 10-Q filed with the SEC on November 13, 2025.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: AstraZeneca PLC: 522,667 shares Alexion Pharmaceuticals, Inc.: 522,667 shares
	(ii) Shared power to vote or to direct the vote: AstraZeneca PLC: 0 shares Alexion Pharmaceuticals, Inc.: 0 shares
	(iii) Sole power to dispose or to direct the disposition of: AstraZeneca PLC: 522,667 shares Alexion Pharmaceuticals, Inc.: 522,667 shares
	(iv) Shared power to dispose or to direct the disposition of: AstraZeneca PLC: 0 shares Alexion Pharmaceuticals, Inc.: 0 shares
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

AstraZeneca PLC

Signature:	/s/ Matthew Bowden
Name/Title:	Matthew Bowden / Company Secretary
Date:	02/06/2026

Alexion Pharmaceuticals, Inc.

Signature:	/s/ Todd Spalding
Name/Title:	Todd Spalding / Secretary
Date:	02/06/2026